Cyclerion Therapeutics, Inc.
(NASDAQ : CYCN)

( )
CYCN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 2.54%53.730.9%$2578.87m
JNJJohnson & Johnson -2.37%155.960.7%$1216.03m
MRKMerck & Co., Inc. 0.00%74.890.7%$1134.23m
LLYEli Lilly & Co. -2.55%248.341.1%$731.87m
BMYBristol-Myers Squibb Co. -1.85%53.631.0%$692.49m
ABBVAbbVie, Inc. -1.41%115.241.9%$609.56m
AZNAstraZeneca Plc -1.26%54.831.0%$288.05m
NVSNovartis AG -0.72%79.690.2%$175.76m
GSKGlaxoSmithKline Plc -0.56%41.130.2%$174.09m
VTRSViatris, Inc. -1.68%12.310.0%$138.06m
DRNADicerna Pharmaceuticals, Inc. -0.18%38.010.3%$135.01m
BFRIBiofrontera, Inc. -15.63%5.990.0%$129.02m
RPRXRoyalty Pharma Plc -3.80%39.770.1%$117.73m
RGENRepligen Corp. -1.61%286.506.7%$114.53m
PTPIPetros Pharmaceuticals, Inc. -28.50%2.860.0%$96.83m

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.